Comparing Empagliflozin vs Farxiga
Empagliflozin | Farxiga (dapagliflozin) |
|
---|
Empagliflozin | Farxiga (dapagliflozin) |
|
|||||||
---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Chronic Kidney Disease, Type 2 Diabetes, Heart Failure, Cardiovascular Risk Reduction. Empagliflozin may also be used for purposes not listed in this medication guide. |
Prescription only
Farxiga is an oral medication that is used alongside diet and exercise to lower blood glucose levels in adults and children aged 10 years and older with type 2 diabetes. It may also be used to... View more |
Related suggestions Type 2 Diabetes
Heart Failure (Congestive Heart Failure)
Chronic Kidney Disease
|
|||||||
More about Empagliflozin | More about Farxiga (dapagliflozin) | ||||||||
Ratings & Reviews | |||||||||
Empagliflozin has an average rating of 5.4 out of 10 from a total of 349 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 41% reported a negative effect. |
Farxiga has an average rating of 4.6 out of 10 from a total of 164 ratings on Drugs.com. 26% of reviewers reported a positive effect, while 47% reported a negative effect. |
||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Empagliflozin side effects |
View all Farxiga side effects |
||||||||
Drug Class | |||||||||
Generic Availability | |||||||||
N/A |
|||||||||
Pricing and Coupons * Prices are without insurance | |||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Farxiga prices |
||||||||
Dosage Forms | |||||||||
N/A |
|
||||||||
Brand Names | |||||||||
Jardiance |
N/A |
||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
12.4 hours |
12.9 hours |
||||||||
CSA Schedule 1 View glossary of CSA terms | |||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | |||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
Drug Interactions | |||||||||
A total of 432 drugs are known to interact with Empagliflozin:
|
A total of 374 drugs are known to interact with Farxiga:
|
||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
Disease Interactions | |||||||||
First Approval Date | |||||||||
August 01, 2014 |
January 08, 2014 |
||||||||
WADA Class View classifications | |||||||||
N/A |
N/A |
||||||||
More Information | |||||||||
Patient Resources | |||||||||
Professional Resources | |||||||||
Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Farxiga
Farxiga (dapagliflozin) is an oral prescription medication that may be given to certain adults with ...
Jardiance
Jardiance (empagliflozin) is used to treat type 2 diabetes, chronic kidney disease and reduce the ...
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Kerendia
Kerendia is used for the treatment of patients with chronic kidney disease (CKD) associated with ...
Dapagliflozin
Dapagliflozin (Farxiga) is an SGLT2 inhibitor that is mainly used alongside diet and exercise to ...
Semaglutide
Semaglutide is a GLP-1 agonist used for weight loss, type 2 diabetes, and reducing cardiovascular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.